211 related articles for article (PubMed ID: 30070923)
1. Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.
Glintborg B; Lindström U; Aaltonen K; Kristianslund EK; Gudbjornsson B; Chatzidionysiou K; Askling J; Nordström D; Hetland ML; Di Giuseppe D; Dreyer L; Kristensen LE; Jørgensen TS; Eklund K; Grondal G; Ernestam S; Joensuu J; Törmänen M; Skydsgaard H; Hagfors J; Kvien TK; Lie E; Fagerli K; Geirsson AJ; Jonsson H; Provan SA; Krogh NS; Jacobsson L
Scand J Rheumatol; 2018 Nov; 47(6):465-474. PubMed ID: 30070923
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis.
Kim SH; Kim HR; Lee SH; Shin K; Kim HA; Min HK
Sci Rep; 2021 Nov; 11(1):21555. PubMed ID: 34732807
[TBL] [Abstract][Full Text] [Related]
3. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
Hetland ML; Jensen DV; Krogh NS
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
Lund Hansen R; Schoedt Jørgensen T; Dreyer L; Hetland ML; Glintborg B; Askling J; Di Giuseppe D; Jacobsson LTH; Wallman JK; Nordstrom D; Aaltonen K; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Love TJ; Kristensen LE
Rheumatology (Oxford); 2021 Jan; 60(1):140-146. PubMed ID: 32591790
[TBL] [Abstract][Full Text] [Related]
5. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI.
Marona J; Sepriano A; Rodrigues-Manica S; Pimentel-Santos F; Mourão AF; Gouveia N; Branco JC; Santos H; Vieira-Sousa E; Vinagre F; Tavares-Costa J; Rovisco J; Bernardes M; Madeira N; Cruz-Machado R; Roque R; Silva JL; Marques ML; Ferreira RM; Ramiro S
RMD Open; 2020 Jan; 6(1):. PubMed ID: 32144137
[TBL] [Abstract][Full Text] [Related]
6. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
7. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
8. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.
Rahman P; Choquette D; Bensen WG; Khraishi M; Chow A; Zummer M; Shaikh S; Sheriff M; Dixit S; Sholter D; Psaradellis E; Sampalis JS; Letourneau V; Lehman AJ; Nantel F; Rampakakis E; Otawa S; Shawi M
BMJ Open; 2016 Apr; 6(4):e009661. PubMed ID: 27048632
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry.
Mease PJ; Blachley T; Malatestinic WN; Harrold LR; Dube B; Lisse JR; Bolce RJ; Hunter TM
Curr Med Res Opin; 2024 Feb; 40(2):315-323. PubMed ID: 38050693
[TBL] [Abstract][Full Text] [Related]
10. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study.
Hellgren K; Ballegaard C; Delcoigne B; Cordtz R; Nordström D; Aaltonen K; Gudbjornsson B; Love TJ; Aarrestad Provan S; Sexton J; Zobbe K; Kristensen LE; Askling J; Dreyer L
Rheumatology (Oxford); 2021 Aug; 60(8):3656-3668. PubMed ID: 33401297
[TBL] [Abstract][Full Text] [Related]
11. Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers.
Saeed A; Khan M; Elmamoun M; Brady M; Morrissey S; Fraser AD
Rheumatol Int; 2012 May; 32(5):1305-9. PubMed ID: 21286722
[TBL] [Abstract][Full Text] [Related]
12. Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
Madsen OR
Rheumatol Int; 2018 Mar; 38(3):425-432. PubMed ID: 29299630
[TBL] [Abstract][Full Text] [Related]
13. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
[TBL] [Abstract][Full Text] [Related]
14. Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset.
Griffiths H; Smith T; Mack C; Leadbetter J; Butcher B; Acar M; Ciciriello S
J Rheumatol; 2022 Feb; 49(2):150-156. PubMed ID: 34334362
[TBL] [Abstract][Full Text] [Related]
15. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.
Bergstra SA; Branco JC; Vega-Morales D; Salomon-Escoto K; Govind N; Allaart CF; Landewé RBM
Ann Rheum Dis; 2018 Oct; 77(10):1413-1420. PubMed ID: 29980576
[TBL] [Abstract][Full Text] [Related]
16. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
[TBL] [Abstract][Full Text] [Related]
17. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
[TBL] [Abstract][Full Text] [Related]
18. Is the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry.
Farisoğulları B; Yardımcı GK; Sarı A; Bilgin E; Bölek EÇ; Duran E; Kılıç L; Akdoğan A; Karadağ Ö; Apraş Bilgen Ş; Ertenli Aİ; Kiraz S; Kalyoncu U
Clin Exp Rheumatol; 2022 Jan; 40(1):112-119. PubMed ID: 33635221
[TBL] [Abstract][Full Text] [Related]
19. Consensus development on eligibility of government subsidisation of biologic disease modifying anti-rheumatic agents for treatment of ankylosing spondylitis: The Singapore experience.
Cheung PP; Lahiri M; Teng GG; Lui NL; Chia FL; Koh DR; Koh WH; Ng SC; Suresh E; Leong KP; Lim AYN; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1517-1526. PubMed ID: 26177789
[TBL] [Abstract][Full Text] [Related]
20. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
